BCR-ABL mbcr

• About this biomarker
• Introduction to our products
• Why choose our products
• Main products for BCR-ABL mbcr
• Associated products
• Related publications

The BCR-ABL fusion gene is associated with formation of the Philadelphia chromosome (Ph) and is one of the most common genetic abnormalities detected in leukemia.

In Acute Lymphoblastic Leukemia (ALL), Ph is detected in 20-40 % of adult and 2-5 % of childhood cases.

At the molecular level, the Ph chromosome or t(9;22) results from the translocation of the 5’ part of the BCR gene (chromosome 22) to the 3' part of ABL gene (chromosome 9). The corresponding fusion gene BCR-ABL, in ALL patients, is transcribed into an mRNA with 1 junction variant e1a2 that encodes for a chimeric protein, p190, with elevated tyrosine kinase activity.

BCR-ABL mbcr FusionQuant® technology uses Real-Time Quantitative PCR to quantify the BCR-ABL mbcr fusion gene transcripts relative to ABL, BCR or GUS control genes.

The technology used for quantification of BCR-ABL mbcr has been standardized in the EAC (Europe Against Cancer) program  [Gabert J et al. Leukemia. 2003, Beillard E et al. Leukemia. 2003], and IPSOGEN FusionQuant® kits use this validated technology to calibrate and normalize RQ-PCR results.

Why choose BCR-ABL mbcr FusionQuant® kits?

• EAC Standardized RQ-PCR procedures

• Compatibility with most RQ-PCR platforms

• Calibrated and sensitive quantification of fusion gene transcript, normalized with ABL (BCR or GUS) control gene (results in NCN)

• Product manufactured under ISO 13485 certification ensuring optimal quality control and full traceability

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.
Leukemia. 2003
Authors: Gabert J et al.

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.
Leukemia. 2003
Authors: Beillard E et al.